Industry
Life Sciences
Patient-centered Care Models Taking Center Stage in Life Sciences
Highlights
- While traditional control towers improved transparency and visibility, they did not fundamentally change how decisions were made.
- The next generation of manufacturing control towers seeks to enhance the decision-making and reasoning capabilities of agentic AI to assist and augment operators or take autonomous decisions.
- The manufacturing control tower is no longer a window into operations—it is becoming the operating system of the modern pharmaceutical plant.
On this page
On this pageinpage
How can control towers accelerate decision-making besides improving transparency and visibility?
For years, manufacturing control towers have focused on visibility—unifying data from historians, Manufacturing Execution Systems (MES), Enterprise Resource Planning (ERP) systems, Supervisory Control and Data Acquisition (SCADA) systems, and other operational systems into a centralised dashboard.
While this improved transparency and visibility, it did not fundamentally change how decisions were made. Human supervisors still had to interpret data, diagnose issues, and coordinate actions across the plant.
The next generation of manufacturing control towers harnesses the decisioning and reasoning capabilities of Agentic AI to assist and/or augment operators or take autonomous decisions based on the risk level. Thus, control towers are evolving from systems of visibility into systems of intelligence and action.
How does an agentic AI-based control tower accelerate decision making?
Consider a typical production day. A process drift begins developing in a granulation step. Traditional systems may only detect the issue once process limits are exceeded. When a process drift is detected, multiple agents assess the risk, determine operational impact, coordinate corrective actions, and monitor outcomes—all within minutes.
So, an agentic control tower identifies the trend early, compares it against a golden batch profile, predicts the potential impact on yield, and recommends corrective actions before a deviation occurs.
An agentic AI-based manufacturing control tower functions as the operational brain of the plant. It continuously monitors production, predicts disruptions, orchestrates responses, and increasingly automates routine decisions. Instead of simply reporting an incident, it actively helps determine what should happen next.
It is not the intelligence of any single agent, but the collaboration between agents that makes this approach powerful.
For regulated industries such as pharmaceuticals, governance remains essential. Human-in-the-loop controls, audit trails, role-based approvals, and Good [x] Practice (GxP)-compliant decision workflows ensure that autonomy is introduced responsibly and transparently.
What are the various agents that are required for autonomous pharma operations?
The agentic control tower, which drives autonomous pharma operations, is envisioned as a knowledge-centric expert system(s) of specialised AI agents working together. The agents include:
- Batch tracking agents that maintain real-time visibility of batch progression and genealogy.
- Process drift and anomaly agents identify emerging risks and predict failures.
- Bottleneck optimisation agents continuously improve throughput and asset utilisation.
- Scheduling agents dynamically reoptimise production plans in response to changing conditions.Material coordination agents anticipate shortages and prevent line stoppages.
- Maintenance agents predict equipment failures and align interventions with production schedules.
- Operator guidance agents provide real-time SOP and process recommendations.
- Autonomous control agents adjust parameters within approved operating ranges to maintain process performance.
How can agentic control towers deliver value to pharma organisations?
The business impact is significant. Pharma organisations can expect improvements in throughput, reductions in unplanned downtime, better schedule adherence, lower process variability, and faster responses to operational disruptions. Most importantly, manufacturing teams spend less time firefighting and more time optimising performance.
So, what’s the real differentiator, and how can pharma organisations ensure they maximise the real potential of agentic AI?
The real differentiator of the agentic control tower lies in the synchronised, context-aware, and governed orchestration.
The following are a few best practices:
- Design for accelerating and improving decision-making rather than for dashboards.
- Establish a unified manufacturing data model with strong governance, lineage and provenance.
- Ensure there is a unified knowledge fabric or connected organisational intelligence.
- Assign shared goals and KPIs to agents and establish human-in-the-loop governance.
- Enable continuous agentic learning through closed-loop feedback systems and simulation-based validation.
- Ensure transparency and explainability for AI decision and recommendations.
Way forward
The future of manufacturing is not a plant with more dashboards. It is a plant where intelligent agents continuously sense, predict, decide, and coordinate operations in real time.
The manufacturing control tower is no longer a window into operations—it is becoming the operating system of the modern pharmaceutical plant.